Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erdafitinib - Janssen Pharmaceuticals

Drug Profile

Erdafitinib - Janssen Pharmaceuticals

Alternative Names: BALVERSA; G-024; JNJ-42756493; JNJ-493

Latest Information Update: 05 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Newcastle University
  • Developer Genentech; Janssen Pharmaceutica; Janssen Research & Development; Multiple Myeloma Research Consortium; National Cancer Institute (USA); University Health Network of Toronto; Vanderbilt-Ingram Cancer Center
  • Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urogenital cancer
  • Phase II Bladder cancer; Cholangiocarcinoma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
  • Phase I/II Liver cancer
  • Phase I Breast cancer; Lymphoma

Most Recent Events

  • 27 Sep 2021 Efficacy and adverse events data from a phase Ib/II NORSE trial in Urogenital cancer presented at the European Society for Medical Oncology Annual Congress 2021 (ESMO-2021)
  • 17 Sep 2021 Biomarkers information updated
  • 16 Jun 2021 Johnson & Johnson Pharmaceutical Research & Development plans to re-initiate phase I drug interaction trial for erdafitinib in Belgium (PO) in January 2022 (NCT04330248) (EudraCT2019-003473-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top